摘要
目的:探究雷贝拉唑、克拉霉素、阿莫西林、枸橼酸铋钾四联治疗幽门螺杆菌感染慢性胃炎的疗效。方法:按照入院顺序抽取江西省上饶市广丰区人民医院自2015年2月至2017年2月门诊治疗的HP感染慢性胃炎患者90例,以随机数字法,分为研究组(n=45)和对照组(n=45)。对照组进行阿莫西林、克拉霉素、雷贝拉唑三联疗法,研究组在对照组基础上联合枸橼酸铋钾进行四联治疗。对比两组的HP根除率、治疗效果、不良反应发生率、生活质量。结果:与对照组的HP根除率比较(68.9%),研究组的(88.9%)较高;与对照组的治疗效果(73.3%)比较,研究组的(93.3%)较优,与对照组的生活质量比较,研究组的较高;与对照组的不良反应发生率比较,观察组的较低,差异显著(P<0.05)。结论:雷贝拉唑、克拉霉素、阿莫西林、枸橼酸铋钾四联治疗HP感染慢性胃炎,疗效显著,病情可见明显的改善,HP根除率显著提高,生活质量明显改善,不良反应较少,值得借鉴和推广。
Objective： To explore the effect of rabeprazole, clarithromycin, amoxicillin, and bismuth potassium citrate in the treatment for chronic gastritis quadruple by Helicobacter pylori infection. Methods： 90 cases of HP infection patients in our hospital with chronic gastritis from February 2015 to February 2017 in the outpatient were randomly divided into study group（n=45） and the control group（n=45）. The control group was treated with amoxicillin, clarithromycin, rabeprazole with triple therapy, the study group on the basis of the control group combined with bismuth potassium citrate. HP eradication rate, therapeutic effect, adverse reaction rate, quality of life was compared. Results： Compared with control group（68.9%）, HP eradication rate of the study group（88.9%） was higher than the control group treatment; the quality of life in the study group（93.3%） was the better than the control group（73.3%）; the adverse reaction was significantly lower than the control group（P0.05）. Conclusion： Combined rabeprazole, clarithromycin, amoxicillin and bismuth potassium citrate quadruple therapy for HP infection and chronic gastritis showed good curative effect, with increased eradication rate of HP, improved quality of life and less adverse reaction, thus it is worthy of reference and promotion.
出处
《药品评价》
CAS
2017年第21期42-45,共4页
Drug Evaluation
基金
江西省卫生计生委科技计划(课题编号:20174015)
